JKS Document Store
 Store FrontAccountSearchProduct ListBasket Contents Checkout 
Search For The Following Word(s):
Sign In

Medicinal Products Lifecycle
Medical Devices
Japan Monitor (ISSN 1550-3429)
Information Meetings
Legislation and Agreements
All in Japan (ISSN 1550-3402)
E-health Japan (ISSN 1550-3410)
EU Pharma & Medical Devices
Free documents

All in Japan: Anti-cancers (Enterprise-wide Use License)

All in Japan: Anti-cancers (Enterprise-wide Use License)Quantity in Basket:none
Code: AJ_T_006

ISSN 1550-3402 (Enterprise-wide Use License: This document is identical to the Single User License document (AJ_T_005), however by purchasing the Enterprise-wide Use License here you would be granted a right to distribute the document within your organization or to make the document accessible by more than one user within your organization.) 28-page document. <<>> The reports from the “All in Japan” series (ISSN 1550-3402) provide overview and concise up-to-date description of each product from a specific product or therapeutic category approved in Japan. All in Japan: Anti-cancers report is the first of the sub-series of reports covering exclusively the prescription class therapeutics approved in the oncology field in Japan. <<>> Key Features: Presented in details are selected eight individual active substances: cyclophosphamide, gemcitabine, paclitaxel, doxorubicin, capecitabine, trastuzumab, gefitinib, irinotecan – all approved as medicinal products in Japan. Key package insert information and formulation specification for quick referencing - package inserts version (issued by the pharmaceutical manufacturers, importers or the entities commissioned to market the approved product), formulation, packages, indications, approved doses and schedules. All 25 marketed variants of the products are described by brand, maker/importer and marketer/distributor. <<>> Analysis Highlights: Recently introduced strategy for accelerated approval of product already registered in the major regulatory regions of EU and North America, but yet unapproved in Japan is expected to considerably diversify the cancer treatment options in Japan. The current and the subsequent reports on the anti-cancers in Japan shall provide for the first time in English exhaustive description of the both patented and generic products on the market. <<>> Practical Use to the Reader: Anti-cancer product managers wanting to enter the Japanese market. Regulatory affairs personnel seeking regulatory approval for their oncology product in Japan - an indispensable information source particularly for registration feasibility. Oncology marketing specialists – can evaluate (or reevaluate) their Japan strategy by having access to regulatory information normally unavailable elsewhere. Researchers studying and/or comparing particular makers, markets and/or disease and conditions. Invaluable reference material to confirm or refute current concerns arising from a regulatory strategy to register oncology products in Japan. <<>> Copyright © JKS LLC 2005.

Related Item(s)
Code Name Price    
AJ_T_001 All in Japan: Triptans (Single User License) $425.00
AJ_T_003 All in Japan: Statins (Single User License) $3,450.00
AJ_T_004 All in Japan: Statins (Enterprise-wide Use License) $7,500.00
AJ_T_002 All in Japan: Triptans (Enterprise-wide Use License) $1,950.00
AJ_T_005 All in Japan: Anti-cancers (Single User License) $1,250.00